top of page

Clinical Research

Along with normal clinical service,  wide range of clinical trials also provided in our center

We are actively recruiting patient to participate in the following clinical trials

Please send referral letter to  if interested

Lung Cancer

Protocol Number

Protocol Title

Experimental agent

Principle Investigator


A Phase 3,  Multicenter, Randomized, Double-Blind Study of MK-7684 with Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer

MK-7684A (vibostolimab + pembrolizumab)


An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations

Sacituzumab Govitecan-hziy (SG)

BA 3011-002

A Phase 2 Study of BA3011 Alone and in Combination With PD-1 Inhibitor in Adult Patients With Metastatic Non-small Cell Lung Cancer (NSCLC) Who Had Prior Disease Progression on a PD-1/L-1 Inhibitor

BA3011 +PD-1 inhibitor 

475-0708 MT Lung 

A Phase 2 Open-label Single-arm Study to Evaluate the Combination of Pembrolizumab, Lenvatinib and Chemotherapy in Non-small Cell Lung Cancer (NSCLC) Harbouring Targetable Mutation and Failed Standard Tyrosine Kinase Inhibitors

Pembrolizumab + Lenvatinib + Pemetrexed + Carboplatin

(Velocity 01/02) 

A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients with Lung Cancer

Novel Treatment combination

bottom of page